We chose to focused on PRMT5 because 1) PRMT5 was the top-scoring and druggable hit, 2) literature supports a role for PRMT5 in the progression of various cancer types, including breast cancer24,25, and 3) PRMT5 small molecule inhibitors (PRMT5i) are in clinical development, thus allowing us to test the antitumor effects of PRMT5 pharmacological inhibition. The gene discussed is PRMT5; the disease is cancer.